EPI-001
EPI-001 is a small molecule inhibitor that targets the androgen receptor (AR), a nuclear receptor that plays a critical role in the development and progression of prostate cancer. The term "EPI-001" is pronounced as "E-P-I-zero-zero-one".
Etymology
The term "EPI" in EPI-001 stands for "E-Prostanoid", referring to the class of drugs it belongs to. The "001" signifies that it was the first compound of this class to be discovered.
Mechanism of Action
EPI-001 works by binding to the N-terminal domain (NTD) of the androgen receptor, which is a region of the receptor that is critical for its activity. By binding to this region, EPI-001 prevents the receptor from being activated by androgens, which are hormones that normally stimulate the growth of prostate cancer cells.
Related Terms
See Also
References
- Dehm, S. M., & Tindall, D. J. (2011). Molecular regulation of androgen action in prostate cancer. Journal of cellular biochemistry, 112(2), 365-373.
- Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J. K., ... & Sadar, M. D. (2010). Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer cell, 17(6), 535-546.
External links
- Medical encyclopedia article on EPI-001
- Wikipedia's article - EPI-001
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski